Human BMPR1A (Bone Morphogenetic Protein Receptor, type IA) ELISA Kit (HUES01762)
- SKU:
- HUES01762
- Product Type:
- ELISA Kit
- Size:
- 96 Assays
- Uniprot:
- P36894
- Sensitivity:
- 0.19ng/mL
- Range:
- 0.31-20ng/mL
- ELISA Type:
- Sandwich
- Synonyms:
- CD292, 10q23del, ACVRLK3, ALK3, SKR5, BMPR1-A
- Reactivity:
- Human
- Tested Sample Types:
- Serum, plasma and other biological fluids
Description
Assay type: | Sandwich |
Format: | 96T |
Assay time: | 4.5h |
Reactivity: | Human |
Detection Method: | Colormetric |
Detection Range: | 0.31-20 ng/mL |
Sensitivity: | 0.19 ng/mL |
Sample Volume Required Per Well: | 100µL |
Sample Type: | Serum, plasma and other biological fluids |
Specificity: | This kit recognizes Human BMPR1A in samples. No significant cross-reactivity or interference between Human BMPR1A and analogues was observed. |
This ELISA kit uses Sandwich-ELISA as the method. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human BMPR1A. Standards or samples are added to the appropriate micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human BMPR1A and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well successively and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human BMPR1A, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by adding Stop Solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human BMPR1A. The concentration of Human BMPR1A in samples can be calculated by comparing the OD of the samples to the standard curve.
UniProt Protein Function: | BMPR1A: a serine/threonine-protein kinase receptor for Bone morphogenetic protein-2 and -4 (BMP-2 and BMP-4). Defects in BMPR1A are a cause of juvenile polyposis syndrome (JPS) and Cowden disease (CD), a cancer syndrome characterized by multiple hamartomas and by a high risk for breast, thyroid and endometriel cancers. |
UniProt Protein Details: | Protein type:Protein kinase, Ser/Thr (receptor); Kinase, protein; Membrane protein, integral; Protein kinase, TKL; EC 2. 7. 11. 30; TKL group; STKR family; Type1 subfamily Chromosomal Location of Human Ortholog: 10q22. 3 Cellular Component: cell soma; dendrite; integral to membrane; plasma membrane; caveola Molecular Function:transforming growth factor beta receptor activity; protein serine/threonine kinase activity; protein binding; protein homodimerization activity; metal ion binding; SMAD binding; ATP binding; transmembrane receptor protein serine/threonine kinase activity; receptor signaling protein serine/threonine kinase activity Biological Process: neural plate mediolateral pattern formation; transcription from RNA polymerase II promoter; developmental growth; hindlimb morphogenesis; neural crest cell development; positive regulation of transcription, DNA-dependent; paraxial mesoderm structural organization; mesendoderm development; dorsal/ventral axis specification; palate development; protein amino acid phosphorylation; negative regulation of neurogenesis; BMP signaling pathway; transforming growth factor beta receptor signaling pathway; positive regulation of mesenchymal cell proliferation; ectoderm development; Mullerian duct regression; somitogenesis; in utero embryonic development; lateral mesoderm development; stem cell maintenance; positive regulation of bone mineralization; odontogenesis of dentine-containing teeth; positive regulation of osteoblast differentiation; mesoderm formation; pituitary gland development; cartilage development; embryonic organ development; immune response; embryonic digit morphogenesis; regulation of lateral mesodermal cell fate specification; positive regulation of epithelial cell proliferation; lung development Disease: Juvenile Polyposis Syndrome; Polyposis Syndrome, Hereditary Mixed, 2 |
NCBI Summary: | The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-betas and activins transduce their signals through the formation of heteromeric complexes with 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding. [provided by RefSeq, Jul 2008] |
UniProt Code: | P36894 |
NCBI GenInfo Identifier: | 61252444 |
NCBI Gene ID: | 657 |
NCBI Accession: | P36894. 2 |
UniProt Secondary Accession: | P36894,Q8NEN8, A8K6U9, |
UniProt Related Accession: | P36894 |
Molecular Weight: | Calculated: 60kDaObserved: 69kDa |
NCBI Full Name: | Bone morphogenetic protein receptor type-1A |
NCBI Synonym Full Names: | bone morphogenetic protein receptor, type IA |
NCBI Official Symbol: | BMPR1A |
NCBI Official Synonym Symbols: | ALK3; SKR5; CD292; ACVRLK3; 10q23del |
NCBI Protein Information: | bone morphogenetic protein receptor type-1A; ALK-3; BMPR-1A; BMP type-1A receptor; activin receptor-like kinase 3; activin A receptor, type II-like kinase 3; serine/threonine-protein kinase receptor R5 |
UniProt Protein Name: | Bone morphogenetic protein receptor type-1A |
UniProt Synonym Protein Names: | Activin receptor-like kinase 3; ALK-3; Serine/threonine-protein kinase receptor R5; SKR5; CD_antigen: CD292 |
Protein Family: | Bone morphogenetic protein receptor |
UniProt Gene Name: | BMPR1A |
UniProt Entry Name: | BMR1A_HUMAN |
As the OD values of the standard curve may vary according to the conditions of the actual assay performance (e. g. operator, pipetting technique, washing technique or temperature effects), the operator should establish a standard curve for each test. Typical standard curve and data is provided below for reference only.
Concentration (ng/mL) | O.D | Average | Corrected |
20 | 2.286 2.312 | 2.299 | 2.208 |
10 | 1.505 1.535 | 1.52 | 1.429 |
5 | 0.948 0.918 | 0.933 | 0.842 |
2.5 | 0.486 0.524 | 0.505 | 0.414 |
1.25 | 0.265 0.263 | 0.264 | 0.173 |
0.63 | 0.196 0.172 | 0.184 | 0.093 |
0.31 | 0.132 0.146 | 0.139 | 0.048 |
0 | 0.087 0.095 | 0.091 | -- |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, mid range and high level Human BMPR1A were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, mid range and high level Human BMPR1A were tested on 3 different plates, 20 replicates in each plate.
Intra-assay Precision | Inter-assay Precision | |||||
Sample | 1 | 2 | 3 | 1 | 2 | 3 |
n | 20 | 20 | 20 | 20 | 20 | 20 |
Mean (ng/mL) | 1.01 | 2.12 | 6.77 | 1.07 | 2.18 | 6.21 |
Standard deviation | 0.05 | 0.12 | 0.26 | 0.07 | 0.12 | 0.20 |
C V (%) | 4.95 | 5.66 | 3.84 | 6.54 | 5.50 | 3.22 |
Recovery
The recovery of Human BMPR1A spiked at three different levels in samples throughout the range of the assay was evaluated in various matrices.
Sample Type | Range (%) | Average Recovery (%) |
Serum (n=5) | 93-106 | 98 |
EDTA plasma (n=5) | 87-100 | 92 |
Cell culture media (n=5) | 93-108 | 101 |
Linearity
Samples were spiked with high concentrations of Human BMPR1A and diluted with Reference Standard & Sample Diluent to produce samples with values within the range of the assay.
Serum (n=5) | EDTA plasma (n=5) | Cell culture media (n=5) | ||
1:2 | Range (%) | 94-109 | 96-111 | 86-97 |
Average (%) | 100 | 103 | 92 | |
1:4 | Range (%) | 87-98 | 88-102 | 85-100 |
Average (%) | 92 | 93 | 92 | |
1:8 | Range (%) | 87-98 | 82-94 | 86-100 |
Average (%) | 93 | 89 | 93 | |
1:16 | Range (%) | 87-99 | 80-91 | 84-96 |
Average (%) | 94 | 86 | 91 |
An unopened kit can be stored at 4°C for 1 month. If the kit is not used within 1 month, store the items separately according to the following conditions once the kit is received.
Item | Specifications | Storage |
Micro ELISA Plate(Dismountable) | 8 wells ×12 strips | -20°C, 6 months |
Reference Standard | 2 vials | |
Concentrated Biotinylated Detection Ab (100×) | 1 vial, 120 µL | |
Concentrated HRP Conjugate (100×) | 1 vial, 120 µL | -20°C(shading light), 6 months |
Reference Standard & Sample Diluent | 1 vial, 20 mL | 4°C, 6 months |
Biotinylated Detection Ab Diluent | 1 vial, 14 mL | |
HRP Conjugate Diluent | 1 vial, 14 mL | |
Concentrated Wash Buffer (25×) | 1 vial, 30 mL | |
Substrate Reagent | 1 vial, 10 mL | 4°C(shading light) |
Stop Solution | 1 vial, 10 mL | 4°C |
Plate Sealer | 5 pieces | |
Product Description | 1 copy | |
Certificate of Analysis | 1 copy |
- Set standard, test sample and control (zero) wells on the pre-coated plate and record theirpositions. It is recommended to measure each standard and sample in duplicate. Note: addall solutions to the bottom of the plate wells while avoiding contact with the well walls. Ensuresolutions do not foam when adding to the wells.
- Aliquot 100 µL of standard solutions into the standard wells.
- Add 100 µL of Sample / Standard dilution buffer into the control (zero) well.
- Add 100 µL of properly diluted sample (serum, plasma, tissue homogenates and otherbiological fluids) into test sample wells.
- Cover the plate with the sealer provided in the kit and incubate for 90 min at 37 °C.
- Aspirate the liquid from each well, do not wash. Immediately add 100 µL of BiotinylatedDetection Ab working solution to each well. Cover the plate with a plate seal and gently mix. Incubate for 1 hour at 37 °C.
- Aspirate or decant the solution from the plate and add 350 µL of wash buffer to each welland incubate for 1-2 minutes at room temperature. Aspirate the solution from each well andclap the plate on absorbent filter paper to dry. Repeat this process 3 times. Note: a microplatewasher can be used in this step and other wash steps.
- Add 100 µL of HRP Conjugate working solution to each well. Cover with a plate seal andincubate for 30 min at 37 °C.
- Aspirate or decant the solution from each well. Repeat the wash process for five times asconducted in step 7.
- Add 90 µL of Substrate Reagent to each well. Cover with a new plate seal and incubate forapproximately 15 min at 37 °C. Protect the plate from light. Note: the reaction time can beshortened or extended according to the actual color change, but not by more than 30min.
- Add 50 µL of Stop Solution to each well. Note: Adding the stop solution should be done inthe same order as the substrate solution.
- Determine the optical density (OD value) of each well immediately with a microplate readerset at 450 nm.